Curasight Beheer

Beheer criteriumcontroles 2/4

De CEO Curasight is Ulrich Krasilnikoff, benoemd in Jan2016, heeft een ambtstermijn van 8.83 jaar. bezit rechtstreeks 19.25% van de aandelen van het bedrijf, ter waarde DKK 43.39M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.8 jaar en 8.8 jaar.

Belangrijke informatie

Ulrich Krasilnikoff

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	8.8yrs
Eigendom CEO	19.2%
Management gemiddelde ambtstermijn	8.8yrs
Gemiddelde ambtstermijn bestuur	8.8yrs

Recente managementupdates

Recent updates

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

Aug 29

CEO

Ulrich Krasilnikoff (57 yo)

8.8yrs

Tenure

Mr. Ulrich Alexander Krasilnikoff has been Chief Executive Officer, Chief Financial Officer and Executive Director at Curasight A/S since 2016. Mr. Krasilnikoff served as an Associate Partner at Capidea Ma...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ulrich Krasilnikoff	CEO, CFO & Executive Director	8.8yrs	geen gegevens	19.25% DKK 43.4m
Jacob Madsen	Co-Founder & Director CMC	11.8yrs	geen gegevens	4.4% DKK 9.9m
Andreas Kjaer	Co-Founder	11.8yrs	geen gegevens	29.09% DKK 65.6m
Hanne Jensen	Chief Development Officer & COO	2.8yrs	geen gegevens	0.19% DKK 433.7k
Nic Gillings	Head of Quality Assurance & Regulatory Affairs	3.4yrs	geen gegevens	geen gegevens

8.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CURAS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ulrich Krasilnikoff	CEO, CFO & Executive Director	8.8yrs	geen gegevens	19.25% DKK 43.4m
Andreas Kjaer	Co-Founder	11.8yrs	geen gegevens	29.09% DKK 65.6m
Kirsten Drejer	Chairman of the Board	3.4yrs	geen gegevens	0.019% DKK 43.4k
Lars Trolle	Independent Deputy Chairman of the Board	10.8yrs	geen gegevens	2.84% DKK 6.4m
Charlotte Vedel	Independent Deputy Chairman of the Board	4.8yrs	geen gegevens	0.19% DKK 433.7k

8.8yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CURAS wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.8 jaar).

Curasight Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Curasight A/S Announces Board Changes

Curasight A/S, Annual General Meeting, Mar 21, 2024

Curasight A/S, Annual General Meeting, Mar 24, 2022

Recent updates

Curasight A/S Announces Clinical Supply Agreement with Curium for uTREAT® Development and Commercialization

Curasight A/S Announces International Patent Application for uTREAT® to Broaden IP Protection

Curasight A/S Publishes Clinical Phase II Trial of uPAR-PET in Brain Cancer Patients; Data Supports Development of uTREAT for Brain Cancer

New major risk - Financial position

Curasight A/S to Report Q3, 2024 Results on Nov 21, 2024

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

New minor risk - Shareholder dilution

Curasight A/S to Report Q2, 2024 Results on Aug 22, 2024

Curasight A/S to Report Q3, 2024 Results on Jul 02, 2024

New major risk - Share price stability

New major risk - Financial position

Curasight A/S to Report Q1, 2024 Results on May 23, 2024

Less than half of directors are independent

Curasight A/S Announces Approval of Clinical Trial Application (CTA) for Phase 2 Trial with uTRACE in Prostate Cancer Patients

Curasight A/S Announces Board Changes

Curasight A/S has withdrawn its Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S, Annual General Meeting, Mar 21, 2024

Curasight A/S has filed a Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S to Report Fiscal Year 2023 Results on Feb 22, 2024

Curasight Gears Up for Phase II Study in Prostate Cancer

Curasight A/S to Report Q3, 2023 Results on Nov 24, 2023

New minor risk - Share price stability

Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer (NSCLC)

Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Curasight A/S to Report Q2, 2023 Results on Aug 24, 2023

Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer

Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)

Curasight A/S to Report Fiscal Year 2022 Results on Feb 23, 2023

Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors

Curasight A/S Announces Recruitment Completes in uPAR-PET Study in Brain Cancer

Curasight A/S, Annual General Meeting, Mar 24, 2022

Curasight A/S Announces Positive Data of uTREAT® in Glioblastoma Provides "Green Light" to Proceed with Next Steps

New 90-day high: kr.41.50

New 90-day high: kr.34.45

Curasight Announces Results from Phase II Study in Prostate Cancer to Be Published in the Journal of Nuclear Medicine

Curasight A/S to Report Q1, 2021 Results on May 20, 2021

Curasight A/S Initiates Pre-Clinical Study on Therapy in Brain Cancer and Signs CRO-Agreement

Curasight A/S has completed an IPO in the amount of DKK 32.688 million.

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd